Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
Tyler Smith, Maya Madhavan, Daniel Gratch, Aneek Patel, Valerie Saha, Carrie Sammarco, Zoe Rimler, Guadalupe Zuniga, Dunia Gragui, Leigh Charvet, Gary Cutter, Lauren Krupp, Ilya Kister, Lana Zhovtis Ryerson
Topics & Concepts
FingolimodMedicineNatalizumabMultiple sclerosisInternal medicineOcrelizumabCoronavirus disease 2019 (COVID-19)DiseaseSeverity of illnessProgressive multifocal leukoencephalopathyRituximabImmunologyInfectious disease (medical specialty)LymphomaMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersLong-Term Effects of COVID-19